

Valeant Pharmaceuticals International, Inc.

Form 3

March 15, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Fraidin Stephen

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

03/08/2016

3. Issuer Name and Ticker or Trading Symbol

Valeant Pharmaceuticals International, Inc. [VRX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer ☐ Other
 (give title below) (specify below)

PERSHING SQUARE
CAPITAL MANAGEMENT,
L.P., 888 SEVENTH
AVENUE, 42ND FLOOR

(Street)

NEW YORK, NY 10019

(City)

(State)

(Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

No Securities beneficially owned ⁽¹⁾0 ⁽¹⁾D ⁽¹⁾ A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
No Securities beneficially owned <u>(1)</u>	Â <u>(1)</u>	Â <u>(1)</u>	No Securities beneficially owned ⁽¹⁾	0 <u>(1)</u>	\$ <u>(1)</u>	D <u>(1)</u>	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Fraidin Stephen PERSHING SQUARE CAPITAL MANAGEMENT, L.P. 888 SEVENTH AVENUE, 42ND FLOOR NEW YORK, NY 10019	Â X	Â	Â	Â

Signatures

by: Nicholas Zanoni for Stephen Fraidin 03/15/2016

 Signature of Reporting Person

 Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

No securities are beneficially owned. The reporting person disclaims beneficial ownership of the shares of and derivatives related to the common stock of the Issuer reported as beneficially owned by Pershing Square Capital Management L.P., PS Management GP, LLC and William A. Ackman, and accordingly this report does not include such shares and derivatives.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.